Changes in Macular Pigment Optical Density and Serum Lutein Concentration in Japanese Subjects Taking Two Different Lutein Supplements

• Published in: PloS one Vol. 10; no. 10; p. e0139257
• Main Authors: Obana, Akira, Tanito, Masaki, Gohto, Yuko, Okazaki, Shigetoshi, Gellermann, Werner, Bernstein, Paul S.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 09.10.2015; Public Library of Science (PLoS)
• Subjects: Acuity; Adult; Age; Antioxidants; Bioavailability; Calendula; Carotenoids; Comparative studies; Contrast Sensitivity; Dietary supplements; Dietary Supplements - analysis; Eye color; Female; Formulations; Glare; Hospitals; Humans; Japan; Laboratories; Lutein; Lutein - administration & dosage; Lutein - blood; Lutein - therapeutic use; Macular degeneration; Macular Degeneration - prevention & control; Macular Pigment - analysis; Macular Pigment - metabolism; Male; Medicine; Middle Aged; Optical density; Photonics; Physiochemistry; Physiological aspects; Prospective Studies; Retina; Sensitivity; Spectrometry; Spectrum analysis; Statistical analysis; Statistical significance; Studies; Supplements; Visual Acuity; Xanthophyll; Zeaxanthin; Zeaxanthins - administration & dosage; Zeaxanthins - blood; Zeaxanthins - therapeutic use; Japan; United States; United States > US; Utah
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0139257

To investigate macular pigment optical density (MPOD) and serum concentration changes of lutein in Japanese subjects participating in a clinical trial in which two formulations of lutein and zeaxanthin supplements with different physiochemical properties are used. Thirty-six healthy volunteers were recruited into this prospective, randomized, parallel-group, double-masked comparative study at a single institute. Two products were used, FloraGLO® (Kemin Japan) and XanMax® (Katra Phytochem). The lutein particle size and zeaxanthin concentrations differed between the formulations. The subjects consumed one of the two supplements for a duration of up to 6 months. MPOD levels were measured by resonance Raman spectrometry at baseline and once a month until the end of the study. Serum lutein concentration was measured at baseline, month 3, and month 6. The subjects were also tested for contrast sensitivity, glare sensitivity, visual acuity, and in addition had a focal electroretinogram measured. The mean serum lutein concentrations increased significantly after the first three months, but the mean MPOD levels in either supplement group did not show any statistically significant increase. A detailed analysis, however, revealed three response patterns in both groups for the increase of MPOD levels and serum lutein concentration, i.e. "retinal responders", who had an increase of both MPOD levels and serum lutein concentrations (n = 13), "retinal non-responders", who had only increased serum concentrations and no change in MPOD levels (n = 20), and "retinal and serum non-responders", who had neither MPOD level nor plasma concentration increases (n = 3). The subjects with low MPOD levels at baseline appeared to show increased MPOD levels at the 6 month time point upon lutein supplementation (r = -0.4090, p = 0.0133). Glare sensitivity improved in retinal responders in both supplement groups, while there were no remarkable changes in contrast sensitivity. No statistically significant differences could be detected for MPOD levels and serum lutein concentrations between the two investigated lutein supplement formulations. Responses to lutein supplementation regarding MPOD levels and serum lutein concentrations varied between subjects. Subjects with lower MPOD levels at baseline responded well to lutein supplementation. However, since the number of subjects was low, a further study with more subjects is needed to prove that subjects with low MPOD levels will benefit from lutein supplementation. UMIN-CTR UMIN000004593.